Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer

被引：1

作者：

Azadeh, Payam ^{[1
]}

Mortazavi, Nafiseh ^{[2
]}

Tahmasebi, Arezoo ^{[3
]}

Kamal, Farnaz Hosseini ^{[4
]}

Novin, Kambiz ^{[1
]}

机构：

[1] Shahid Beheshti Univ Med Sci, Dept Clin Oncol, Tehran 1617763141, Iran

[2] Shahid Beheshti Univ Med Sci, Dept Pathol, Tehran 1617763141, Iran

[3] Amirkabir Univ Technol, Dept Math & Comp Sci, Tehran, Iran

[4] Chalmers Univ CTH, Dept Chem & Biol Engn, Gothenburg, Sweden

来源：

CHEMOTHERAPY | 2015年 / 61卷 / 01期

关键词：

Cetuximab; Chemotherapy; Metastatic colorectal cancer; KRAS; PHASE-II TRIAL; 1ST-LINE TREATMENT; FLUOROURACIL; OXALIPLATIN; IRINOTECAN; LEUCOVORIN; CAPECITABINE; 2ND-LINE; EFFICACY; FOLFOX6;

D O I：

10.1159/000440693

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: The aim of this study was to compare the efficacy and hematologic toxicity of cetuximab combined with various types of chemotherapy regimens in patients with KRAS wild-type metastatic colorectal cancer (mCRC). Methods: The response rate, progression-free survival (PFS) and overall survival of the patients were analyzed. Results: In total, 45 patients were included in the study. The overall response rate for the combination of cetuximab and FOLFOX, FOLFIRI and CAPOX was 20, 46 and 30%, respectively, but the differences were not statistically significant. The median PFS for the three groups were 8, 6 and 3.5 months, respectively, but again these differences were not significant. All-grade leukopenia and anemia for the cetuximab plus FOLFOX group were significantly higher than for the other chemotherapy regimens. Conclusion: Our findings suggest that the combination of cetuximab and the three standard chemotherapy regimens resulted in the same outcomes in our patient population of mCRC, with higher hematologic toxicities among the FOLFOX subgroup. (C) 2015 S. Karger AG, Basel

引用

页码：51 / 56

页数：6

共 17 条

[1]

[Anonymous], COMM TOX CRIT CTC V4

[2]

[Anonymous], 2020, CA Cancer J Clin, DOI DOI 10.3322/CAAC.21590

[3] Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study [J].

Bokemeyer, C. ;

Bondarenko, I. ;

Hartmann, J. T. ;

de Braud, F. ;

Schuch, G. ;

Zubel, A. ;

Celik, I. ;

Schlichting, M. ;

Koralewski, P. .

ANNALS OF ONCOLOGY, 2011, 22 (07) :1535-1546

[4] Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK [J].

Borner, M. ;

Koeberle, D. ;

Von Moos, R. ;

Saletti, P. ;

Rauch, D. ;

Hess, V. ;

Trojan, A. ;

Helbling, D. ;

Pestalozzi, B. ;

Caspar, C. ;

Ruhstaller, T. ;

Roth, A. ;

Kappeler, A. ;

Dietrich, D. ;

Lanz, D. ;

Mingrone, W. .

ANNALS OF ONCOLOGY, 2008, 19 (07) :1288-1292

[5] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

[6] Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].

Douillard, JY ;

Cunningham, D ;

Roth, AD ;

Navarro, M ;

James, RD ;

Karasek, P ;

Jandik, P ;

Iveson, T ;

Carmichael, J ;

Alakl, M ;

Gruia, G ;

Awad, L ;

Rougier, P .

LANCET, 2000, 355 (9209) :1041-1047

[7] Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study [J].

Eichler, K. ;

Dufas, T. ;

Hammerstingl, R. ;

Gruber-Rouh, T. ;

Vogl, T. J. ;

Zangos, S. .

CHEMOTHERAPY, 2013, 59 (01) :66-73

[8] A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].

Goldberg, RM ;

Sargent, DJ ;

Morton, RF ;

Fuchs, CS ;

Ramanathan, RK ;

Williamson, SK ;

Findlay, BP ;

Pitot, HC ;

Alberts, SR .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30

[9]

Lenz H., 2014, ANN ONCOL, V25, pv1, DOI [10.1093/annonc/mdu438.13, DOI 10.1093/ANNONC/MDU438.13]

[10] Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104-A Randomized Trial of the German AIO CRC Study Group [J].

Moosmann, Nicolas ;

von Weikersthal, Ludwig Fischer ;

Stauch, Martina ;

Hass, Holger G. ;

Dietzfelbinger, Herrmann ;

Oruzio, Daniel ;

Klein, Stefan ;

Zellmann, Klaus ;

Decker, Thomas ;

Schulze, Mathias ;

Abenhardt, Wolfgang ;

Puchtler, Gerhard ;

Kappauf, Herbert ;

Mittermueller, Johann ;

Haberl, Christopher ;

Schalhorn, Andreas ;

Jung, Andreas ;

Stintzing, Sebastian ;

Heinemann, Volker .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) :1050-1058

← 1 2 →